| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 07/03/2025 | 22:30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 06/03/2025 | 14:00 | GlobeNewswire Inc. | ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 05/03/2025 | 13:52 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 24/01/2025 | 22:05 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 17/01/2025 | 22:05 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 30/12/2024 | 14:30 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 27/12/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 20/12/2024 | 23:04 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 20/12/2024 | 22:15 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 18/12/2024 | 13:55 | GlobeNewswire Inc. | ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 20/11/2024 | 13:55 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 15/11/2024 | 14:35 | GlobeNewswire Inc. | Life Sciences Investor Forum: Presentations Now Available for Online Viewing | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 14/11/2024 | 14:10 | GlobeNewswire Inc. | ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 14/11/2024 | 14:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 05/11/2024 | 13:00 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 29/10/2024 | 12:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 22/10/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 17/10/2024 | 13:50 | GlobeNewswire Inc. | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 15/10/2024 | 13:50 | GlobeNewswire Inc. | ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 07/10/2024 | 13:55 | GlobeNewswire Inc. | ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 16/09/2024 | 23:30 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 09/09/2024 | 22:35 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 09/09/2024 | 22:32 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 09/08/2024 | 22:40 | GlobeNewswire Inc. | ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 07/08/2024 | 13:50 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 29/07/2024 | 13:45 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 25/07/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 19/07/2024 | 03:35 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 18/07/2024 | 17:18 | GlobeNewswire Inc. | ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
| 09/07/2024 | 13:57 | GlobeNewswire Inc. | ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 | NASDAQ:ZVSA | ZyVersa Therapeutics Inc |
